​

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MDGL Stock Forecast

Madrigal Pharmaceuticals (MDGL) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $677.00, with a high of $962.00 and a low of $542.00. This represents a 23.84% increase from the last price of $546.66.

$200 $360 $520 $680 $840 $1 High: $962 Avg: $677 Low: $542 Last Closed Price: $546.66

MDGL Stock Rating

Madrigal Pharmaceuticals stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (88.00%), 2 Hold (8.00%), 1 Sell (4.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 2 22 Strong Sell Sell Hold Buy Strong Buy

MDGL Price Target Upside V Benchmarks

TypeNameUpside
StockMadrigal Pharmaceuticals23.84%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-420
Avg Price Target-$709.75$668.90
Last Closing Price$546.66$546.66$546.66
Upside/Downside-29.83%22.36%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 263131--17
Aug, 263122--17
Jul, 262112--15
Jun, 261102--13
May, 263112--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 04, 2026Wolfe Research$605.00$482.0025.52%10.67%
Jul 31, 2026Barclays$962.00$493.1195.09%75.98%
Jul 29, 2026Canaccord Genuity$587.00$538.808.95%7.38%
Jul 27, 2026Wells Fargo$685.00$544.5125.80%25.31%
Jun 11, 2026Morgan Stanley$542.00$471.3215.00%-0.85%
May 13, 2026Truist Financial$709.00$513.3038.13%29.70%
May 07, 2026Evercore ISI$649.00$539.7320.25%18.72%
May 07, 2026Canaccord Genuity$578.00$539.737.09%5.73%
Jan 27, 2026Barclays$964.00$500.3992.65%76.34%
Jan 14, 2026Andrea TanGoldman Sachs$571.00$493.9015.61%4.45%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 04, 2026Wolfe ResearchPeer PerformOutperformupgrade
Aug 03, 2026BarclaysOverweightOverweighthold
Jul 31, 2026UBSBuyBuyhold
Jul 27, 2026Wells FargoOverweightOverweightinitialise
Jul 17, 2026CitigroupOutperformOutperformhold
Jun 24, 2026Piper SandlerOverweightOverweighthold
Jun 11, 2026Bank of America SecuritiesNeutralNeutralhold
Jun 01, 2026Wells FargoOverweightupgrade
Jan 27, 2026BarclaysOverweightinitialise
Jan 20, 2026CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-50 $-20 $10 $40 $70 $100 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.99$-21.90$-12.85---
Avg Forecast$-19.44$-23.62$-12.97$2.87$32.05$57.26
High Forecast$-18.30$-22.60$-3.19$9.94$46.90$75.38
Low Forecast$-20.11$-24.76$-22.28$-4.22$7.13$34.14
Surprise %2.83%-7.28%-0.93%---

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$180.13M$958.40M---
Avg Forecast-$172.04M$514.95M$1.02B$1.88B$2.92B
High Forecast-$182.74M$633.56M$1.02B$1.94B$3.64B
Low Forecast-$161.27M$412.06M$1.02B$1.82B$2.02B
Surprise %-4.71%86.12%---

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-373.63M$-465.89M$-288.28M---
Avg Forecast$-373.63M$-442.50M$-297.44M$117.58M$782.67M$1.07B
High Forecast$-342.06M$-422.26M$-59.61M$185.69M$876.45M$1.41B
Low Forecast$-375.85M$-462.74M$-416.30M$-78.80M$133.33M$637.91M
Surprise %-5.29%-3.08%---

MDGL Forecast FAQ

Is Madrigal Pharmaceuticals stock a buy?

Madrigal Pharmaceuticals stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Madrigal Pharmaceuticals is a favorable investment for most analysts.

What is Madrigal Pharmaceuticals's price target?

Madrigal Pharmaceuticals's price target, set by 25 Wall Street analysts, averages $677 over the next 12 months. The price target range spans from $542 at the low end to $962 at the high end, suggesting a potential 23.84% change from the previous closing price of $546.66.

How does Madrigal Pharmaceuticals stock forecast compare to its benchmarks?

Madrigal Pharmaceuticals's stock forecast shows a 23.84% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Madrigal Pharmaceuticals over the past three months?

  • September 2026: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 17.65% Strong Buy, 70.59% Buy, 11.76% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 13.33% Strong Buy, 73.33% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.

What is Madrigal Pharmaceuticals’s EPS forecast?

Madrigal Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $2.87, marking a -122.33% decrease from the reported $-12.85 in 2025. Estimates for the following years are $32.05 in 2027, and $57.26 in 2028.

What is Madrigal Pharmaceuticals’s revenue forecast?

Madrigal Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $1.02B, reflecting a 6.43% increase from the reported $958.4M in 2025. The forecast for 2027 is $1.88B, and $2.92B for 2028.

What is Madrigal Pharmaceuticals’s net income forecast?

Madrigal Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $117.58M, representing a -140.79% decrease from the reported $-288M in 2025. Projections indicate $782.67M in 2027, and $1.07B in 2028.